Loading stock data…
$17.76-0.64 (-3.48%)
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Denali Therapeutics Inc. in the Healthcare sector is trading at $17.76 with a market capitalization of $3.4B. Wall Street consensus targets $35.75 (16 analysts), implying a +101.3% move over the next 12 months. The stock is currently 35% below its 52-week high of $27.30, remaining 16.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.60M | $0 | $0 | $0 | $0 |
| Gross Profit | $3.51M | — | — | — | $0 |
| Operating Income | -$130.54M↑ | -$137.36M | -$137.37M | -$137.43M↓ | -$134.96M |
| Net Income | -$127.55M↑ | -$128.45M | -$128.55M↓ | -$126.90M↓ | -$124.12M |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflamma...